Novartis, Boehringer DTC platforms slash prices for Cosentyx, Spiriva Respimat

Novartis and Boehringer Ingelheim have announced the launch of new direct-to-patient platforms aimed at significantly reducing the prices of their widely used medications, Cosentyx and Spiriva Respimat, respectively. This strategic move aligns with the ongoing pressure from the U.S. government to lower drug costs and reflects broader industry trends as pharmaceutical companies seek to enhance patient access to essential therapies.

By joining the ranks of other major players like AstraZeneca and Bristol Myers Squibb, Novartis and Boehringer are not only responding to regulatory demands but also positioning themselves competitively in a market increasingly focused on affordability. The implications of these price reductions could be far-reaching, potentially influencing patient adherence to treatment regimens and reshaping the pharmaceutical pricing landscape as companies navigate the complexities of value-based care.